Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Milrinone

Milrinone

pharmaceutical raw materials
Milrinone structure

Milrinone 

structure
  • CAS No:

    78415-72-2

  • Formula:

    C12H9N3O

  • Chemical Name:

    Milrinone

  • Synonyms:

    [3,4′-Bipyridine]-5-carbonitrile,1,6-dihydro-2-methyl-6-oxo-;1,6-Dihydro-2-methyl-6-oxo[3,4′-bipyridine]-5-carbonitrile;Win 47203;Milrinone;Corotrope;Primacor IV;Corotrop;Milrila;Primacor;2-Hydroxy-6-methyl-5-(pyridin-4-yl)pyridine-3-carbonitrile

  • Categories:

    Active Pharmaceutical Ingredients  >  Circulatory System Drugs

Description

Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.


Solid


Milrinone is a member of the class of bipyridines that is 2-pyridone which is substituted at positions 3, 5, and 6 by cyano, pyrid-4-yl, and methyl groups, respectively. It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. It has a role as an EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor, a platelet aggregation inhibitor, a vasodilator agent and a cardiotonic drug. It is a pyridone, a nitrile and a member of bipyridines.|A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the ionotropic potency of amrinone.|Milrinone is a Phosphodiesterase 3 Inhibitor. The mechanism of action of milrinone is as a Phosphodiesterase 3 Inhibitor.|A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone.

Milrinone Basic Attributes

211.22

211.22

278-903-6

JU9YAX04C7

760072

DTXSID5023324

C01CE02|C - Cardiovascular system

2933399090

Characteristics

65.8

0

off-white powder

1.3±0.1 g/cm3

>300 °C

448.7ºC at 760 mmHg

225.2±28.7 °C

1.622

soluble in DMSO( >10 mg/mL). Insoluble in water.

2-8°C

150.4 Ų [M+H]+ [CCS Type: TW, Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Safety Information

III

6.1(b)

UN 2811 6.1/PG 3

3

23/24/25-26/27/28

36/37/39-45-22

DW1762000

T,T+

Stable. Incompatible with strong oxidizing agents.

Missing Phrase - N15.00950417-P261-P280-P302 + P352 + P312-P304 + P340 + P312-P403 + P233

H301 + H311 + H331

|Danger|H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]|P261, P264, P270, P271, P280, P301+P310, P302+P352, P304+P340, P311, P312, P321, P322, P330, P361, P363, P403+P233, P405, and P501|Aggregated GHS information provided by 106 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

LD50 = 0.3 mg/L in rats

70 to 80%

Drug Information

Indicated for the treatment of congestive heart failure.|FDA Label

Milrinone, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)|Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)|Compounds that specifically inhibit PHOSPHODIESTERASE 3. (See all compounds classified as Phosphodiesterase 3 Inhibitors.)|Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)

Milrinone is rapidly and almost completely absorbed after oral administration. Bioavailability is 92% (in healthy volunteers).|The primary route of excretion of milrinone in man is via the urine.|0.38 liters/kg [intravenous injections of 12.5 mcg/kg to 125 mcg/kg to congestive heart failure patients]|0.13 L/kg/hr [congestive heart failure patients, following IV injections of 12.5 mcg/kg to 125 mcg/kg]

There are five metabolites but the O-glucuronide represents the major pathway of biotransformation.

2.3 hours

Milrinone inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, Milrinone also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity.

Corotrop

Milrinone Use and Manufacturing

Uses

Selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity. Cardiotonic

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients|Pharmaceuticals

Computed Properties

Molecular Weight:211.22
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:3
Rotatable Bond Count:1
Exact Mass:211.074561919
Monoisotopic Mass:211.074561919
Topological Polar Surface Area:65.8
Heavy Atom Count:16
Complexity:419
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Positive inotropic and vasodilatory effects

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • HIKMA PHARMACEUTICALS LLC

    United States United States
    Active
  • EMCURE PHARMACEUTICALS LTD

    United States United States
    Active
  • W R GRACE AND CO -CONN

    United States United States
    Active

Recommended Suppliers of Milrinone

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.